Idefirix Expansion SERB has secured exclusive development and commercialization rights to Idefirix (imlifidase) for the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and the MENA region, with a deal valued at €115 million. This regional expansion creates a sizeable addressable market in transplant therapies and enables co-promotion, distribution, and regulatory support partnerships with transplant centers, distributors, and government programs.

US Emergency Demand The May 2026 US launch of ThyroSafe 130 mg potassium iodide tablets demonstrates SERB's capability to deliver critical medicines into the US market. Potential sales opportunities include direct hospital distribution, partnerships with hospital networks and distributors serving disaster preparedness programs, and inclusion in federal or state stockpile contracts.

Oncology Expansion SERB's acquisition of Y-mAbs strengthens its oncology and antibody-based therapeutics portfolio, opening doors with cancer centers, academic hospitals, and biotechnology partnerships. Opportunities include supply agreements for antibodies, co-promotion or collaboration on clinical trials, and manufacturing support for expanding biologics lines.

Global Distribution With a footprint across 100+ countries and more than 70 essential medicines, SERB offers a scalable platform for global market access. BD opportunities include partnering with multinational hospital systems, regional distributors, and contract manufacturers to accelerate entry of new therapies and broaden access to existing medicines in regulated markets.

Growth Momentum Leadership and scale position SERB for enterprise deals. CEO Vanessa Wolfeler’s tenure since 2024 combined with a revenue base of 250–500 million and a 501–1000 employee base signals execution strength for large, cross-therapy partnerships, cross-selling opportunities, and joint ventures leveraging the company’s digital capabilities.